Novmetapharma is a company that is currently developing innovative new drugs based on differentiated mechanisms (activation of AMPK Sirt 1 and Nrf2 pathways) using new substances for metabolic diseases and aims to enter the global metabolic disease treatment market through original technologies and efficient development systems